Quantifying atherogenic lipoproteins for lipid-lowering strategies : Consensus-based recommendations from EAS and EFLM

Show full item record



Permalink

http://hdl.handle.net/10138/327217

Citation

European Atherosclerosis Soc , European Federation Clinical Chem , Nordestgaard , B G , Langlois , M R , Langsted , A & Laitinen , P 2020 , ' Quantifying atherogenic lipoproteins for lipid-lowering strategies : Consensus-based recommendations from EAS and EFLM ' , Atherosclerosis , vol. 294 , pp. 46-61 . https://doi.org/10.1016/j.atherosclerosis.2019.12.005

Title: Quantifying atherogenic lipoproteins for lipid-lowering strategies : Consensus-based recommendations from EAS and EFLM
Author: European Atherosclerosis Soc; European Federation Clinical Chem; Nordestgaard, Borge G.; Langlois, Michel R.; Langsted, Anne; Laitinen, Päivi
Contributor: University of Helsinki, HUSLAB
Date: 2020-02
Language: eng
Number of pages: 16
Belongs to series: Atherosclerosis
ISSN: 0021-9150
URI: http://hdl.handle.net/10138/327217
Abstract: The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (= total - HDL cholesterol) constitute the primary lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDL cholesterol is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDL cholesterol shall be measured or calculated by the same method to attenuate errors in treatment decisions due to marked between-method variations. Lipoprotein(a)-cholesterol is part of measured or calculated LDL cholesterol and should be estimated at least once in all patients at risk of ASCVD, especially in those whose LDL cholesterol decline poorly upon statin treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDL cholesterol or apolipoprotein B, especially in patients with mild-to-moderate hypertriglyceridemia (2-10 mmol/L). Non-HDL cholesterol includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels. Additional apolipoprotein B measurement can detect elevated LDL particle numbers often unidentified on the basis of LDL cholesterol alone. Reference intervals of lipids, lipoproteins, and apolipoproteins are reported for European men and women aged 20-100 years. However, laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds.
Subject: Atherosclerotic cardiovascular disease
LDL cholesterol
Remnant cholesterol
non-HDL cholesterol
Apolipoprotein B
Lipoprotein(a)
CORONARY-HEART-DISEASE
NON-HDL CHOLESTEROL
TRIGLYCERIDE-RICH LIPOPROTEINS
CARDIOVASCULAR RISK REDUCTION
NUCLEAR-MAGNETIC-RESONANCE
APOLIPOPROTEIN-B LEVELS
DIVISION WORKING GROUP
LDL-CHOLESTEROL
FAMILIAL HYPERCHOLESTEROLEMIA
CLINICAL-CHEMISTRY
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
untitled.pdf 879.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record